Objective:
To evaluate the effectiveness and safety of suprachoroidal triamcinolone acetonide in treating macular edema associated with uveitis in a real-world setting.
Key Findings:
- A single injection of suprachoroidal triamcinolone acetonide provided durable relief from UME for most patients.
- The incidence of significant intraocular pressure (IOP) elevations was low and manageable, even in patients with a history of glaucoma or ocular hypertension.
- Recommended follow-up for IOP monitoring at 1, 3, 6, and every 3 months thereafter.
Interpretation:
Suprachoroidal triamcinolone acetonide is a safe and effective treatment for UME, particularly for patients at risk of steroid-induced ocular hypertension.
Limitations:
- The study is observational and may not account for all variables affecting treatment outcomes.
- Data was drawn from a registry, which may have inherent biases.
Conclusion:
Suprachoroidal triamcinolone acetonide should be considered for patients with a history of glaucoma or those at risk for elevated IOP due to its low incidence of significant IOP increases and predictable timing of any changes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
